OmniAb Results Presentation Deck

Cash Position Provides Long Operational Runway ($ millions) 12/31/22 Cash Balance* Teclistamab/TECVAYLI First Commercial Sale Milestones Received in January 2023 Proforma Cash Position * Includes cash, cash equivalents and short-term investments $88 $35 $123 BUSINESS IS CLOSE TO BREAK-EVEN CASH FLOW EXPECT TO END 2023 WITH SLIGHTLY MORE CASH THAN 12/31/22 CASH BALANCE CURRENT CASH BALANCE AND CASH FROM OPERATIONS EXPECTED TO PROVIDE SUFFICIENT CAPITAL TO FUND OPERATIONS FOR FORESEEABLE FUTURE 18 OmniAb

View entire presentation